Analyst Price Targets — SPRB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 27, 2026 12:05 pm | Albert Lowe | Craig-Hallum | $140.00 | $55.63 | TheFly | Spruce Biosciences initiated with a Buy at Craig-Hallum |
| December 23, 2025 11:26 am | — | Oppenheimer | $283.00 | $82.82 | TheFly | Spruce Biosciences initiated with an Outperform at Oppenheimer |
| November 11, 2025 10:52 am | — | JMP Securities | $259.00 | $115.61 | TheFly | Spruce Biosciences price target raised to $259 from $254 at Citizens JMP |
| October 28, 2025 8:41 am | — | JMP Securities | $254.00 | $123.02 | TheFly | Spruce Biosciences upgraded to Outperform from Market Perform at Citizens JMP |
| October 21, 2025 6:38 pm | — | Leerink Partners | $160.00 | $134.00 | StreetInsider | Spruce Biosciences, Inc. (SPRB) PT Raised to $160 at Leerink PartnersMember Login |
Latest News for SPRB
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the pricing of its previously announced underwritten public offering of 1,150,000 shares of its common stock at a price to the…
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its…
The average of price targets set by Wall Street analysts indicates a potential upside of 181.2% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 208.3% in Spruce Biosciences (SPRB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the year ended December 31, 2025 and provided corporate updates. “2025 was a very productive year, and our team continues to execute…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SPRB.
U.S. House Trading
No House trades found for SPRB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.